Company news

CStone Pharmaceuticals news in 2026

CStone Pharmaceuticals's news releases, calls and decks from 2026, newest first.

View company

Monthly return of equity issuer on movements in securities for the month ended 31 October 2026

November 5, 2026

Voluntary announcement - cstone and kimia therapeutics enter clinical development collaboration to advance a novel drug candidate targeting repair pathways critical for solid tumor survival

November 3, 2026

Voluntary announcement - cstone announces major clinical validation milestone for CS2009 at ESMO 2026: data from more than 300 patients support mechanism, safety and broad antitumor activity

October 25, 2026

Monthly return of equity issuer on movements in securities for the month ended 30 September 2026

October 7, 2026

Interim report 2026

September 28, 2026

Voluntary announcement - increase in shareholding by CEO and executive director dr. jianxin yang by 496,000 shares, with accumulated purchase totaling 14,210,500 shares

September 24, 2026

CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum

August 27, 2026

CStone Pharmaceuticals Enters into Exclusive Commercialization Agreement with Arrotex for Sugemalimab across Australia and New Zealand

June 25, 2026

CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) ASCO 2026 Key Highlights

June 11, 2026

ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept

May 31, 2026

CStone Presented Preclinical Data for Three Novel or Differentiated ADCs at AACR 2026, Including CS5007 (EGFR/HER3)

April 19, 2026

CStone Announces 2025 Annual Results: Accelerated Expansion of Global Commercial Footprint and Efficient Advancement of Innovation Pipeline 2.0

March 26, 2026

CStone Announces MHRA Approval in UK for Sugemalimab in Stage III NSCLC

February 22, 2026

CStone Announces FDA Clearance of IND Application for Its Novel Trispecific Antibody CS2009 to Advance into Phase II Clinical Trial

February 16, 2026

CStone Announces FDA Clearance of IND Application for Its Novel Trispecific Antibody CS2009 (PD-1/VEGF/CTLA-4) to Advance into Phase II Clinical Trial

February 15, 2026

Decks in 2026